As transgender medical care becomes unfairly politicized, presentations such as ENDO 2022’s Meet the Professor session “Beginner’s Guide to Gender-Affirming Hormone Therapy for Transgender and Gender Diverse Adults” are more essential than ever. Attendees will be shown a variety of best practices in providing affirming care to transgender and gender diverse adults. On the...
ENDO 2022 attendees will have the option to attend in person in Atlanta, Ga., or tune in online. To make your virtual attendance go as smoothly as possible, Endocrine News reached out to previous virtual attendees to get their tips on how to make the most of your online experience. When ENDO 2022 gets under...
Study finds undertreatment can lead to longer stay and higher readmission rates. Undertreatment with thyroid hormone replacement can put patients with hypothyroidism at risk for worse hospital outcomes, including longer length of stay and higher rates of readmission, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology and Metabolism. Hypothyroidism, or...
Our first hybrid ENDO 2022 includes enhanced experiences for attendees from in-person networking events to new opportunities for endocrine scientists that you surely will not want to miss. Our team is working hard to make sure this ENDO is the best one yet and is dedicated to revamping the experience to include in-person features to...
The controversy around the use of radioactive iodine to treat hyperthyroidism will be addressed at this year’s all-virtual ENDO 2021 in the session, “Does the Treatment of Hyperthyroidism Lead to Cancer?” Both sides of this issue give us a preview of what to expect from what promises to be a lively discussion. This month’s ENDO...
A poster presented at ENDO 2021 appears to show promise for a new treatment aimed at patients with Cushing’s syndrome. The poster, presented by Strongbridge Biopharma, plc, a global commercial-stage biopharmaceutical company, announced that detailed results from the previously reported Phase 3 LOGICS study of RECORLEV® (levoketoconazole) in patients with endogenous Cushing’s syndrome were presented...
At ENDO 2021, the first time the Endocrine Society’s annual conference has gone all-virtual, a live Presidential Plenary on March 20 will feature a pair of presentations on the latest developments in basic tissue engineering. Nobel Prize winner Brian Kobilka, MD, talks to Endocrine News about his session, “Structural Insights into G Protein-Coupled Receptor Activation:...
A relatively new field, transgender medicine will be featured in the ENDO 2021 session, “Transgender Care: A Comprehensive Assessment for a Multi-Faceted Condition,” a live, 90-minute program taking place Sunday, March 21, 2021, at 12:15 p.m. Program co-chair, Stephen M. Rosenthal, MD, and Sabine Hannema, MD, PhD, talk to Endocrine News about what attendees can...
As transgender medical care becomes unfairly politicized, presentations such as ENDO 2022’s Meet the Professor session “Beginner’s Guide to Gender-Affirming Hormone Therapy for Transgender and Gender Diverse Adults” are more essential than ever. Attendees will be shown a variety of best practices in providing affirming care to transgender and gender diverse adults. On the...
Our first hybrid ENDO 2022 includes enhanced experiences for attendees from in-person networking events to new opportunities for endocrine scientists that you surely will not want to miss. Our team is working hard to make sure this ENDO is the best one yet and is dedicated to revamping the experience to include in-person features to...
At ENDO 2021, the first time the Endocrine Society’s annual conference has gone all-virtual, a live Presidential Plenary on March 20 will feature a pair of presentations on the latest developments in basic tissue engineering. Nobel Prize winner Brian Kobilka, MD, talks to Endocrine News about his session, “Structural Insights into G Protein-Coupled Receptor Activation:...
